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Summary Blurb 
Absence of integral sarcolemmal protein, dystrophin, disrupts the RhoA-actin-SRF cascade in 
skeletal muscle, with subsequent dysregulation of downstream-SRF circadian targets and 





Absence of dystrophin, an essential sarcolemmal protein required for muscle contraction, 
leads to the devastating muscle-wasting disease Duchenne muscular dystrophy. Dystrophin 
has an actin-binding domain, which binds and stabilises filamentous-(F)-actin, an integral 
component of the RhoA-actin-serum-response-factor-(SRF)-pathway. This pathway plays a 
crucial role in circadian signalling, whereby the suprachiasmatic nucleus (SCN) transmits 
cues to peripheral tissues, activating SRF and transcription of clock-target genes. Given 
dystrophin binds F-actin and disturbed SRF-signalling disrupts clock entrainment, we 
hypothesised dystrophin loss causes circadian deficits. We show for the first time alterations 
in the RhoA-actin-SRF-signalling-pathway, in dystrophin-deficient myotubes and dystrophic 
mouse models. Specifically, we demonstrate reduced F/G-actin ratios, altered MRTF levels, 
dysregulated core-clock and downstream target-genes, and down-regulation of key 
circadian genes in muscle biopsies from Duchenne patients harbouring an array of 
mutations. Further, we show dystrophin is absent in the SCN of dystrophic mice which 
display disrupted circadian locomotor behaviour, indicative of disrupted SCN signalling. 
Therefore, dystrophin is an important component of the RhoA-actin-SRF-pathway and novel 







Skeletal muscle is a dynamic structure in which myofilament turnover, maintenance and 
energy replenishment occur continually throughout the day [1]. Circadian transcriptomic 
studies in skeletal muscle indicate that approximately 3.4% of expressed skeletal muscle 
genes show rhythmicity, and that this differs between muscle types, specifically slow and 
fast muscle [2]. These rhythmic genes are involved in many central processes such as 
myogenesis, muscle lipid utilisation, protein metabolism and organisation of myofilaments, 
and very recently a key circadian gene, Bmal1 (Arntl), was shown to be involved in impaired 
myogenicity in muscle of dystrophic mice [3]. 
 
Dystrophin is an integral sarcolemmal protein essential for muscle contraction and 
maintenance, absence of which leads to the devastating muscle wasting disease Duchenne 
muscular dystrophy (DMD) [4, 5]. Dystrophin has an actin-binding domain at the amino-
terminus of the full-length isoform [6-8], which specifically binds and stabilises filamentous 
(F)-actin [9], an integral component of the RhoA-actin-serum response factor (SRF)-pathway 
[10-12]. The RhoA-actin-SRF-pathway is well described in muscle [13], and has since been 
shown to play an essential role in circadian signalling via systemic cues activating SRF in 
peripheral tissues [11]. Indeed SRF is a pivotal nuclear transcription factor, regulating over 
200 target genes [14] that are predominantly involved in cell-growth, migration, cytoskeletal 
organisation and myogenesis[15, 16], and one of the earliest SRF target genes to be 
identified was Dmd [13]. This integral relationship, combined with the understanding that 
the RhoA-actin-SRF-pathway operates via a feed-back loop [17], intimates that the absence 
of dystrophin would have serious implications on SRF regulation.  Indeed, in the reciprocal 
situation, in studies designed to mimic age related sarcopenia by disrupting skeletal muscle 
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SRF expression, this resulted in atrophy, fibrosis, lipid accumulation and disturbed 
regeneration [18] which are all hallmarks of the DMD phenotype [19-21] further supporting 
their cyclical nature and mutual dependence.  
 
Gerber’s revolutionary work on the circadian regulation of the RhoA-actin-SRF pathway, 
eloquently describes how the hypothalamic suprachiasmatic nucleus (SCN), transmits 
systemic cues thereby activating RhoA in peripheral tissues [11]. They demonstrate that 
diurnal polymerisation (F-actin) and de-polymerisation (globular (G)-actin) of actin 
influences SRF expression and transcription of specific downstream circadian targets (Per1 
and Per2) and output genes (Nr1d1 and Rora1) [11, 12]. However, disruption of this 
pathway by removing alternative upstream proteins intrinsic to the cascade has not been 
shown. Given the proximity of dystrophin to F-actin (which it specifically binds and 
stabilises) combined with its integral relationship with SRF transcription, we hypothesise 
that dystrophin loss leads to a shift in actin de-polymerisation, which affects SRF expression 




To assess whether dystrophin loss disrupts the RhoA-actin-SRF pathway, an in vitro assay 
was designed using siRNAs targeting the Dmd gene to down-regulate dystrophin protein in a 
skeletal muscle cell line (H2K 2B4 myoblasts) [22]. Differentiated myotubes were 
transfected twice with 100nM siRNA, and collected 49 hours following the second 
transfection, thereby representing circadian time 1 (CT1). Efficient transfection resulted in 
undetectable amounts of dystrophin protein (Fig 1A) and markedly reduced Dmd transcript 
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levels (Fig 1B). Dystrophic conditions resulted in significantly altered RhoA activation (Fig 1C) 
and decreased F/G-actin ratios (Fig 1D). Additionally, there appears to be greater 
cytoplasmic MRTF accumulation under dystrophic conditions (not significantly different; Fig 
1E). To illustrate circadian oscillation patterns of core clock genes involved in the 
transcriptional auto-regulatory feedback loop following abolition of dystrophin, cells were 
collected every 4 hrs over a 24 hr period, and indicate significant alterations (Fig 1F). Per1, 
Per2 and Clock expression were significantly down-regulated at certain time points, whilst 
Cry2 and Arntl1 were upregulated. Expression of other downstream SRF target genes in the 
actin-cascade, Nr1d1 and Acta [12], were also significantly lower in dystrophin deficient 
samples, and interestingly Srf expression was significantly upregulated. Whilst Srf 
upregulation was unexpected, this may be due to activation of alternative compensatory 
pathways such as the ternary complex factor (TCF) family of Ets domain proteins (MAPK 
pathway) which regulates transcription of growth responsive genes [12]. Importantly, Srf 
upregulation does not denote SRF activation via the RhoA-actin pathway, which would 
require nuclear translocation of MRTF. In order to investigate to what extent dystrophin loss 
in human DMD patients resulted in similar biochemical events, we obtained DMD muscle 
biopsies from patients (tissues collected between 8-10am in the morning and patients 
fasted from midnight the evening before biopsy). Interestingly, a wide array of mutations 
showed down-regulation of key RhoA-actin-SRF targets PER1, PER2 and NR1D1 in nearly all 
samples (Fig 1G).  
 
Given these in vitro and biopsy results, we predicted that SRF signalling in peripheral muscle 
would also be interrupted in dystrophic mice, leading to molecular deficits. The dystrophin-
utrophin knockout (dKO) model presents with a severe phenotype that closely recapitulates 
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disease in patients, specifically severe progressive muscular dystrophy, premature death 
and a plenitude of physiological and molecular aberrations [23]. The oscillation patterns of 
core clock genes in the tibialis anterior (TA) muscle of 5 week old male mice were assessed 
over a 24 hour period (double plotted). This model revealed profound alterations in core 
clock gene expression, with markedly similar patterns to that observed in the dystrophic- 
H2K 2B4 myotubes. The amplitude of SRF-target genes Per1, Per2 and Nr1d1 was lower in 5 
week old dKO animals compared to C57BL10 (Fig 2A), suggesting dampened rhythmicity. 
Gene expression of Cry1, Cry2, Arntl, Clock and other downstream targets (Acta and Rora1) 
were all significantly upregulated at various ZTs. As observed in the H2K 2B4 model, Srf 
expression was again upregulated under dystrophic conditions. F/G-actin ratios were 
significantly lower in 5 week old dKO animals compared to control animals (ZT1; Fig 2B) and 
littermate mdx animals (Fig S1), indicating a more profound impact on F-actin in dKO mice 
compared to the less effected mdx model. In dKO animals, the levels of nuclear MRTF 
protein trends lower (Fig 2C, ZT1), and MRTF cytoplasmic protein levels were significantly 
lower (ZT13) compared to control animals, which together suggests there is less total MRTF 
in dKO animals. It is important to note that F/G actin ratios exhibited diurnal changes in 
skeletal muscle of healthy mice (Fig 2B), and MRTF cytoplasmic fraction levels appear to 
oscillate also.  These results, in combination with the in vitro data, confirm that the actin-
pathway is indeed perturbed in muscle due to dystrophin loss, and components within the 
cascade display diurnal alterations. 
 
We further anticipated that systemic cues from the central clock (SCN) to SRF in peripheral 
muscle would be interrupted. Whilst the dKO mouse model closely recapitulates the 
dystrophic phenotype in patients and is a good molecular model for DMD, its severe 
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phenotype including reduced lifespan (approx. 5-8 weeks) and marked reduction in activity, 
preclude extensive locomotor behaviour studies. As such, the less affected dystrophic 
model, mdx, was utilised for this extensive battery of locomotor tests.  We show for the first 
time that dystrophin protein is expressed in the SCN of C57BL10 mice but not mdx animals 
(Fig 3A), and therefore it was pertinent to assess whether there were any obvious 
abnormalities in the circadian locomotor behaviour in dystrophic mice. Wheel-running 
activity of 20 week old (symptomatic) male mdx and C57BL10 mice were recorded under 
various conditions, and representative actograms under 12hr:12hr light-dark (LD), 24hr dark 
(DD), and 24hr light (LL; Fig 3B) are shown. Under normal LD conditions, no significant 
differences in the number of bouts or total activity between mouse cohorts was observed, 
indicating that the endurance level of mdx mice was normal (Fig 3C). This observation was 
valuable for the interpretation of subsequent data, as it indicated differences between 
genotypes was not due to the muscle wasting phenotype of mdx mice, but rather signalling 
cues from the SCN. Interestingly, during the light phase of LD, activity of mdx mice was 
markedly reduced, and they exhibited delayed onset into dark phase (phase angle). 
Following 6-hour phase advance bouts, mdx mice were capable of re-entraining to the 
shifted cycle in a similar manner to control animals (Fig 3D). Animals were then placed in 
DD, where mdx animals again indicated a delayed onset (phase angle) on release into dark 
(Fig 3E), suggesting that their endogenous clock may be out of phase. Again endurance of 
mdx animals was maintained during DD and they ran for a similar period compared to 
C57BL10 animals, however their free running period was significantly shorter (Fig 3F; mdx 
run half an hour shorter). During the DD phase, mice received a light pulse 4-hours after 
they started exercise (CT16), and mdx mice displayed no difference in the ability to shift the 
clocks phase in response to this nocturnal light compared to C57BL10 animals (Fig 3G). In 
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constant light, activity counts for mdx animals dropped dramatically, and free running 
period was also significantly reduced (Fig 3H). When considering our altered dystrophin-
associated-RhoA-actin-SRF cascade hypothesis, altered activity may be due to dystrophin 
loss in the SCN leading to alterations in core clock gene, Per2, which has been associated 
with shorter circadian period and loss of circadian rhythmicity in constant darkness [24]. The 
delayed phase angle in LD and DD, combined with extreme lack of activity during LL suggest 
a severe aversion to light stimuli in mdx animals. Long-term exposure to light has been 
shown to affect neurons in the SCN and reduce rhythmicity [25], which aggravated by the 
loss of dystrophin in the SCN, may explain the considerable changes in activity of mdx mice. 
Altogether, these data demonstrate the SCN is profoundly affected in dystrophic mice.  
 
Male mdx and C57BL10 mice were also subject to repeated bouts of chronic jetlag (JL) 
whereby lighting conditions were advanced 6 hours every week for 5 weeks (mice weighed 
weekly). Age-matched mdx were significantly heavier than C57BL10 mice (15 weeks old at 
start of protocol, 22 weeks by end), therefore a ‘weight matched’ group (12 weeks at start, 
20 weeks at end) was also assessed. ‘Weight matched’ mdx mice significantly increased in 
weight over 5 weeks, whereas there was no increase in weight in the C57BL10 cohort (Fig 
3I). The JL cohorts were further compared to non-jet lagged (NJL) groups. No significant 
differences were observed between JL and NJL C57BL10 cohorts (all mice 22 weeks of age). 
Although NJL mdx animals were significantly heavier than both C57BL10 cohorts, most 
importantly the JL mdx cohort was significantly heavier than all other groups. Jetlag causes 
changes in phase of entrainment in the SCN and peripheral clock [26]. Some clocks entrain 
faster than others which can cause internal desynchrony. If the synchronising signal such as 
SRF is lost (in this case due to disruption of RhoA-actin-SRF cascade), it is anticipated there 
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will be a greater disruption and desynchrony from jetlag protocols leading to changes in 
weight. This would account for why the C57BL10 animals resisted weight gain under the 
short JL conditioning protocol, whereas the mdx animals do. Together these data indicate 
altered signalling between the SCN and peripheral tissues in dystrophin-deficient mdx mice.  
 
As locomotor experiments were performed in the mdx model, gene expression patterns of 
core clock genes in the TA muscle of 20 week old male mice were assessed over a 24 hour 
period (double plotted). A shift in phase was observed for Per1, Per2, Cry1, Cry2 and Arntl1, 
resulting in significant differences in gene expression at certain time-points within the day 
(Fig 4). For instance, the expression of Per2 in mdx mice peaked at ZT5, but in C57L10 
animals peaked at ZT9. Gene expression of downstream SRF target, Rora1, was significantly 
down-regulated (ZT1, ZT17 and ZT21), and minor alterations in Nr1d1 (ZT21) and Acta1 
(ZT1) were observed.  
 
Most importantly we observe alterations in integral components of the RhoA-actin-SRF 
cascade (in particular SRF targets and F/G-actin ratios) in all dystrophic models described. 
Whilst the mdx gene dataset differs to the dKO and H2K 2B4 myotube models, we regard 
the dKO model with greater esteem given its phenotype and correlation with patient 
disease progression [23], which is supported by the biopsy data (Fig 1H). It further correlates 
closely with cell-culture data in which dystrophin is specifically ablated (Fig 1F). However, in 
order to illustrate locomotive aberrations, and systemic cues with the SCN, it was 
imperative we look in the milder mdx model. The remarkable lifespan and generally mild 
phenotype of mdx mice is poorly understood, but it is likely due to multiple compensatory 
events that ensue and may account for the variances observed between the dystrophic 
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models. As multiple inputs can regulate the clock, it is difficult to predict how the clock will 
react when one input is removed. In vivo complexities in the form of protein or signalling 
interactions with serum, hormones (particularly glucocorticoids as Per2 has a glucocorticoid 
receptor-binding site) and neurological signals or mechanisms triggered to compensate for 
disturbed RhoA-actin-SRF pathway may be involved. One such compensatory mechanism is 
upregulation of utrophin, a homologue of dystrophin, which is knocked out in dKO but 
present in mdx mice. Utrophin has been shown to bind and maintain F-actin polymerisation 
and therefore seems an obvious candidate in the RhoA-actin-SRF signalling cascade [27]. We 
show the presence of utrophin gene and protein expression in mdx mice (Fig S2A), however 
in H2K 2B4 myotubes, Utrn gene expression and protein levels were reduced (Fig S2B). 
Similarly, in DMD patient biopsies, UTRN gene expression was down-regulated in all samples 
with the exception of one, which incidentally also showed upregulation of PER1 and PER2 
for that sample (Fig S2C). Indeed, linear regression analysis of UTRN expression versus PER1 
and PER2 indicate a significant correlation pattern (PER1 R= 0.1687, PER2 R= 0.4542; Fig 
S2D).  Thus, utrophin may compensate for dystrophin loss in mdx animals, and loss of both 
utrophin and dystrophin may lead to greater F-actin instability and downstream SRF activity, 
as observed in the H2K 2B4 and dKO data.  
 
To assess the RhoA-actin SRF cascade further, and determine whether ablation of other 
upstream components of the pathway, such as actin, or indeed SRF itself, results in similar 
changes in the expression of target genes, siRNAs were used to specifically knock-down Srf 
and Acta in H2K 2B4 myoblasts. In order to compare with dystrophin knock-down 
experiments, differentiated myotubes were transfected twice with 100nM Srf and Acta 
siRNAs, alongside Dmd transfected myotubes, and collected 49 hours following the second 
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transfection, thereby representing CT1. Myotubes were also treated with lower 
concentrations of siRNA to confirm gene expression was stable and that myotubes were 
healthy (Fig S3). Interestingly, Srf, Acta and Dmd down-regulation, appear to reciprocally 
modulate each other resulting in lower expression of all genes for all cohorts ie. Srf knock-
down results in lower Dmd and Acta gene expression and vice versa (Fig 5). Additionally, all 
siRNA treatment groups resulted in reductions of RhoA-actin-SRF target genes, Per1 and 
Per2, and Nr1d1 and Rora. Together, this illustrates how intertwined and mutually 




Due to the severe repercussions of most genetic disorders, many other symptoms of disease 
are often overlooked, as efforts are primarily aimed at targeting the underlying genetic 
defect. This is most certainly the case for Duchenne muscular dystrophy (DMD), a 
monogenic disorder resulting in muscle wasting and cardiomyopathy in affected boys [28, 
29]. These boys also experience abnormalities in sleeping patterns [30], and nocturnal 
hypoxaemia and hypercapnia [31] which may be attributed to the dystrophic phenotype- 
specifically the deterioration in respiratory muscles. Here we propose this may also be due 
to a circadian deficit.  
 
We show circadian perturbations in a number of dystrophic models and suggest a 
mechanistic rationale for these changes by investigating components of the RhoA-actin-SRF 
cascade. This seemed a logical approach given F-actins interaction with dystrophin, and its 
importance in the RhoA-actin-SRF cascade, which is crucial for muscle homeostasis [11, 13].  
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In the case of healthy muscle, RhoA regulates polymerisation (F-actin) and de-
polymerisation (G-actin; Fig 6). During de-polymerisation G-actin preferentially binds to 
MRTF, but when this shifts to the polymerisation phase the G-actin pool diminishes and 
unbound MRTF translocates to the nucleus and influences SRF expression. SRF activation in 
turn regulates transcription of target genes- Per1, Per2, Rora1, Nr1d1, and Acta. Here we 
propose that the absence of dystrophin reduces F-actin levels resulting in shifts to the de-
polymerised state. G-actin binds to MRTF, which we show remains cytosolic thereby 
hampering SRF activation (Fig 6). Additionally, we show for the first time that dystrophin is 
absent in the SCNs of dystrophic mice, and that these animals exhibit behavioural 
alterations, indicative of disrupted central circadian signalling within the SCN. As such, the 
lack of dystrophin results in circadian disruption that manifests with physiological and 
molecular alterations in dystrophic models.  
 
Given that dystrophin regulates circadian signalling in peripheral tissues, this suggests that 
related dystrophin glycoprotein complex (DGC) proteins may be implicated in dystrophin 
and F-actin tethering, loss of which could also result in circadian dysregulation. Indeed this is 
supported by knock-down of Srf and Acta, alternative components of the RhoA-actin-SRF 
pathway, which also lead to down-regulation of target genes. Thus, muscular dystrophy 
disorders, such as limb-girdle muscular dystrophy [32], in which DGC and sarcomeric 
proteins are affected should be assessed for circadian abnormalities.  
 
It is possible that some pharmacological interventions used to improve the muscle 
phenotype in DMD patients, may have inadvertently modulated circadian rhythm resulting 
in physiological improvements, such as melatonin [33]  and glucocorticoids [34]. These 
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hormones oscillate throughout the day, are highly regulated by sleep-wake cycles, and are 
governed by SCN signalling [35, 36]. This is particularly interesting given that dystrophin is 
absent in the SCN and may have consequential repercussions on endocrinological processes 
in DMD patients. It has also been shown that the glucocorticoid, dexamethasone, induces 
the transcription factor, Klf15, with beneficial ergonomic effects on dystrophic muscle [37]. 
Klf15 regulates a multitude of processes including metabolism [38, 39] and nitrogen 
homeostasis [40], but most importantly does so in a circadian fashion, and has also been 
shown to be altered in another neuromuscular disorder, spinal muscular atrophy [41]. This 
supports our theory that pharmacological interventions, such as dexamethasone, modulate 
circadian pathways.  
 
Dystrophic mice were adversely affected by constant light exposure. LL causes arrhythmicity 
in the long-term, and short-term exposure is a method used for period lengthening which is 
a common feature of the clock in nocturnal rodents. It is uncertain what effect LL would 
have in human subjects, but constant dim light has been used (rather than DD) to unmask 
the central clock, suggesting light augmentation may be an appropriate therapy for DMD 
patients. Other therapies including exercise, dietary modification or drugs to mitigate 
disease pathology (such as lower calcium) [42] may also usefully be investigated in the 
context of DMD treatment. This study therefore reveals both a hitherto an unanticipated 
role for dystrophin in peripheral muscle tissues and novel avenues for further research and 
possible therapeutic intervention applicable to a range of muscular dystrophy disorders.  
 
Materials and Methods 
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The datasets generated during this study are available from the corresponding author on 
reasonable request. 
 
In vitro Dmd knock-down 
H2K 2B4 myoblasts were cultured in flasks coated with Matrigel (Corning) and in DMEM 
culture media supplemented with 2% chick embryo extract (Seralabs), 10% fetal calf serum 
(Gibco) and 1% antibiotics (Gibco); 33⁰C and 10% CO2. Myoblasts require differentiation into 
myotubes in order to produce dystrophin, and therefore differentiation medium containing 
5% horse serum (Gibco) was used (DMEM supplemented with 1% antibiotics). Dystrophin 
was knocked-down using siRNAs targeting the dystrophin transcript (Dharmacon; see Table 
S1). H2K 2B4 cells were transfected with siRNAs (100nM) and lipofectamine RNAiMAX 
(ThermoFisher Scientific) at day 0 and day 2 of the differentiation process. For RhoA GLISA, 
F/G actin and MRTF studies, cells were harvested 49hrs later, on day 4. Experiments were 
performed in duplicate, whereby cells were scraped, pooled and further split into 3 vials for 
downstream analyses (ie. protein, F/G-actin). This experiment was repeated 3 times to 
attain 3 biological replicates. Data shown relative to control siRNA for each experiment. For 
RT-qPCR study, 49hrs after second transfection, media was removed, cells were washed 
with PBS, and serum free media (DMEM supplemented with 10mM HEPES and 2% B27- 
Gibco) was placed in wells. Cells were collected an hour later (CT1), and then every 4hrs 
over a 24hr period. Note: cells were not synchronised with dexamethasone due to the 
known pharmacological effects observed in dystrophic cells which would likely result in 
complicated interpretation of the results.  
 
SRF and actin knock-down 
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H2K 2B4 myoblasts were again cultured in matrigel coated flasks using DMEM culture media 
(2% chick embryo extract, 10% fetal calf serum and 1% antibiotics; 33⁰C and 10% CO2). 
Myoblasts were differentiated using medium containing 5% horse serum (Gibco) in DMEM 
supplemented with 1% antibiotics. Myoblasts were transfected with Srf and Acta siRNAs 
(Dharmacon; see Table S1) using lipofectamine RNAiMAX (ThermoFisher Scientific) at day 0 
and day 2 of the differentiation process. Cells were harvested 49hrs after the second 
transfection, on day 4. 
 
RNA extraction and RT-qPCR 
For patient biopsies, informed consent was obtained from DMD patients’ for standard 
diagnostic purposes, including muscle biopsy.  In addition, we obtained informed consent to 
use muscle biopsies for research activities, according to the Telethon Project N. GGP07011, 
Ethical approval N. 9/2005, 25 October 2005, by the S.Anna University Hospital Local Ethical 
Committee,  Italy.  Patients fasted overnight before the biopsy, which was performed at 8-
10am.  The control RNA was obtained commercially and consists of 2 human skeletal muscle 
samples pooled together (Ambion). RNA was extracted using an RNAeasy kit from Qiagen as 
per manufacturer’s instructions.   
 
For mouse muscle and myotubes, total RNA was extracted from tissue or cells using Trizol 
(Thermo Scientific Technologies).  
 
All RNA was reverse transcribed using a High Capacity cDNA synthesis kit (Applied 
Biosystems). The cDNA was run using TaqMan probes sets (Applied Biosystems) and gene 
specific primer sets for the core clock genes (Integrated DNA Technologies; see Table S1) on 
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the StepOne Real-Time PCR system (Applied Biosystems). Housekeeping genes were 
determined by running geNorm qRT-PCR normalisation kits with samples from patients 
(Human geNorm kit- ge-DD-12-hu; Primer Design), cell culture and each mouse model 
(Mouse geNorm kit- ge-DD-12-hu; Primer Design). Rpl13a was the most stable house-
keeping gene for Patient biopsies, Gapdh for cell culture and dKO samples, and Atp5b was 
the best for mdx samples. Tissues were collected over a 24 hour time course, and data was 
double plotted (48 hours) to better illustrate the oscillation pattern of core clock genes in 
muscle. The nadir was determined as the minimum value across all genotypes and ZT’s and 
applied to all samples; nadir normalised to 1.   
 
RhoA-activity quantification 
RhoA activity was calculated using a RhoA G-LISA Activation Assay kit as per manufacturer’s 
instructions (Cytoskeleton). Briefly, cells were washed, lysed and snap-frozen until required. 
Protein quantification was performed using Precision Red and samples were run on Rho-
GTP ELISA.    
 
F/G actin westerns 
Actin protein levels were calculated using a G-actin/F-actin in vivo Assay Biochem Kit as per 
manufacturer’s instructions (Cytoskeleton). Briefly, samples were lysed and underwent 
ultra-centrifugation to separate fractions. The G-actin supernatant was removed and the F-
actin was resuspended in F-actin depolymerisation solution. Samples were run on 10% Bis-





Nuclear and cytoplasmic fractions were collected from tissue culture samples and dKO 
tissues using the NE-PERTM kit as described in manufacturer’s instructions (ThermoFisher 
Scientific). Samples were run on 10% Bis Tris gels (Thermo Scientific Technologies), blotted 
onto PVDF membrane (Millipore) and probed with Mkl1 (ab115319) and Mkl2 (ab191496; 
Abcam). For nuclear fractions TBP (ab51841; Abcam) was used as loading controls, and for 
cytoplasmic fractions vinculin (hVIN-1; Sigma) and β-actin were used as loading controls. 
Blots were visualised using IRDye 800CW goat-anti rabbit IgG or IRDye 800CW goat-anti 
mouse IgG (Licor) on the Odyssey imaging system. 
 
Dystrophin/Utrophin protein quantification 
Dystrophin and utrophin protein levels were quantified as previously described [43]. Briefly, 
homogenised samples were run on 3-8% Tris-Acetate gels (Thermo Scientific Technologies), 
blotted onto PVDF membrane (Millipore) and probed with DYS1 (Novocastra, dystrophin) or 
MANCHO antibody (KED laboratory- Oxford, utrophin). Blots were visualised using IRDye 
800CW goat-anti mouse IgG (Licor) on the Odyssey imaging system. For dystrophin, vinculin 
(hVIN-1; Sigma) was used as loading control, and for utrophin samples were quantified 
against total protein using Coomassie stain (Sigma).  
 
Animals housing 
All procedures were authorized and approved by the University of Oxford ethics committee 
and UK Home Office (project licence PDFEDC6F0, protocols 19b1, 2 and 4). Investigators 
complied with relevant ethics pertaining to these regulations. Procedures were performed 





In vivo experiments for gene expression, jetlag and wheel-running studies 
All experiments were performed in male dystrophic C57BL/10ScSn-Dmdmdx/J (mdx; JaxLabs), 
C57B/L10ScSn-Utrn tm1Ked Dmdmdx/J (dKO; JaxLabs) and control C57BL/10ScSnJ (C57BL10; 
Envigo and Oxford BSB) mice. For the 24 hour ZT study, mice (5 week old dKO, littermate 
mdx and C57BL10, or 20 week old mdx and C57BL10) were housed under a strict 12:12hr 
light-dark cycle (LD; 400 lux white light) for 2-3 weeks, after which mice were sacrificed 
every 4-6 hrs over a 24 hr time course (n=3-5 for each genotype and time point). Briefly, 
mice were culled by cervical dislocation and eyes removed. Animals during the night cycle 
were culled under dim red light. The TA was dissected, snap frozen and stored at -80°C. 
 
For wheel-running experiments, each mouse was placed in a large cage fitted with a running 
wheel (n= 6 for each genotype). Activity was recorded using the ClockLab console.  Mice 
were first entrained to a 12:12hr LD cycle at 400lux white light for 2 weeks, and then 
underwent 6 hour phase advance entraining, before being placed into constant darkness 
(DD).  
 
For the jetlag weight study, animals were group housed under a normal 12:12 LD cycle (400 
lux white light) for two weeks to establish stable entrainment (n= 3-4 for each genotype and 
condition). The LD cycle was then advanced by 6h every week for 5 weeks. Animals were 
weighed close to ZT13 each week. Animals were culled at the end of the protocol and 





All statistics were performed using SPSS or GraphPad. For experiments including 3 or more 
comparisons, One-way or Two-way ANOVA was performed with either Bonferroni or 
Games-Howell post-hoc corrections.  For the weight gain experiments, a repeated measures 
One-way ANOVA was used to investigate the overall weight gain differences between the 
groups. For experiments between only 2 groups, student’s t-test (Two-tailed) was 
performed.    
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Figure 1. Disruption of RhoA-actin-SRF pathway in dystrophic cells and patient muscle 
biopsies. To mimic dystrophic conditions, H2K 2B4 myotubes were transfected with siRNAs 
targeting the Dmd gene (Dmd siRNA, red), and a non-targeting (NT siRNA, black) siRNA was 
used for control. (A) Dystrophin was successfully down-regulated at protein, and (B) 
transcript level. Additionally, the absence of dystrophin resulted in (C) altered RhoA activity, 
(D) reduced F/G-actin levels, and (E) greater cytoplasmic MRTF accumulation (loading 
controls: nuclear TBP, and cytoplasmic β-actin). For gene transcript studies, cells were 
placed is serum free media and collected over a 24 hour time course (double plotted-48 
hours- to show oscillation pattern). (F) Circadian time (CT) gene expression data indicates 
diurnal oscillation patterns and down-regulation of pertinent core clock genes (Per1 and 
Per2) and down-stream targets for RhoA-actin-SRF (Nr1d1 and Acta1; housekeeping gene- 
Gapdh). (G) Muscle biopsies were obtained from an array of patients with different 
mutations or deletions in the dystrophin genes, and indicate down-regulation of RhoA-actin-
SRF target genes in most cases (housekeeping genes- Rpl13a). All samples were normalised 
to a pooled skeletal muscle sample from 2 healthy volunteers, as indicated by red line. For 
RhoA GLISA, F/G actin ratio and MRTF westerns, data was normalised to NT control (n=3; 
Two-tailed Student’s t-test). For RT-qPCR CT data, the nadir was determined as the 
minimum value across both treatments (Dmd and NT siRNAs) and CTs and applied to all 
samples; nadir normalised to 1 (n=2-3 for each siRNA and time point; Two-way ANOVA with 
Bonferroni post-hoc test performed). Mean values reported with SEM; ***p < 0.001, 
**p < 0.01, *p < 0.05. For uncropped western blot images and loading controls, see Source 




Figure 2. Diurnal changes in RhoA-MRTF-SRF cascade components in tibialis anterior of 
dystrophin-utrophin (dKO) mouse model. Tissues were collected over a 24 hour time course 
and double plotted (48 hours) to better illustrate the (A) oscillation pattern of core clock 
genes in tibialis anterior (TA) of 5 week old dKO animals which were significantly altered 
compared to C57BL10 (Zeitgeber- ZT). Down-stream targets for RhoA-actin-SRF pathway 
(Nr1d1, Rora1 and Acta) and indeed Srf were also altered (Gapdh used as housekeeping 
gene). (B) F/G-actin protein ratios in dKO mice were significantly down-regulated, (C) as 
were cytoplasmic MRTF fraction levels (loading control: nuclear TBP, and cytoplasmic 
vinculin). In addition, C57BL10 animals exhibit diurnal changes in F/G actin ratio and MRTF 
fraction levels. Light and dark periods represented by outlined (light) and solid bars (dark). 
For RT-qPCR ZT data, the nadir was determined as the minimum value across both 
genotypes and ZTs and applied to all samples; nadir normalised to 1 (n=3-4 for each for each 
genotype and time-point). For F/G actin ratio and MRTF westerns, data was normalised to 
C57BL10 (n=3-4). One or Two-way ANOVA with Bonferroni post-hoc test performed. Mean 
values reported with SEM; ***p < 0.001, **p < 0.01, *p < 0.05. For uncropped western blot 






Figure 3. Perturbed circadian rest-activity and response to jet-lag in dystrophic mouse 
model. (A) Dystrophin western blot shows the absence of protein in the SCN of mdx animals 
(vinculin used as loading control). Locomotor behaviour of mdx and C57BL10 mice were 
assessed and representative wheel-running activity blots (B) shown; 12h:12h light:dark cycle 
(LD), dark:dark (DD) and light:light (LL). Data analysed and represented as graphs: (C) 
behaviour during LD, (D) following 6-hour phase advancements, (E) phase angle on release 
into DD, (F) behaviour during DD, (G) phase delay following a light pulse 4-hours post 
exercise commencement, (H) and behaviour during LL. (I) Weights of mice undergoing 5 
week jetlag protocol assessed (C57BL10, mdx age matched and mdx weight matched), as 
well as total body weight of jetlagged (JL) and non-jetlagged (NJL) mdx and C57BL10 
cohorts. Student’s t-test for comparisons between 2 groups (Two-tailed). For weights over 5 
weeks of jetlag: black asterisk on right- one-way ANOVA comparing all 3 cohorts; dollar sign- 
one way ANOVA with Bonferroni post-hoc between each cohort at each time point. For 
body weights with JL and NJL, One-way ANOVA with Bonferroni post-hoc test performed 
(For wheel running activity n=5-6, jetlag study n=3-4; ***p < 0.001, **p < 0.01, *p < 0.05). 





Figure 4. Altered expression of clock genes in tibialis anterior of mdx mouse model. 
Tissues were collected over a 24 hour time course and double plotted (48 hours) to better 
illustrate the oscillation pattern of core clock genes in tibialis anterior (TA) of 20 week old 
mdx animals which were significantly altered compared to C57BL10 (Zeitgeber- ZT). Down-
stream targets for RhoA-actin-SRF pathway (Nr1d1, Acta and Rora1) were also altered 
(Atp5b used as housekeeping gene). Light and dark periods represented by outlined (light) 
and solid bars (dark). The nadir was determined as the minimum value across both 
genotypes and ZTs and applied to all samples; nadir normalised to 1 (n=3-4 for each for each 
genotype and time-point; Two-way ANOVA with Bonferroni post-hoc test performed). Mean 





Figure 5. Abrogation of alternative RhoA-actin-SRF components leads to a reduction in the 
expression of SRF target genes 
H2K 2B4 myotubes were transfected with 100nM siRNAs targeting the Srf, Acta and Dmd 
genes (Srf siRNA, blue, Acta siRNA grey and Dmd siRNA, red), and a non-targeting (NT siRNA, 
black) siRNA was used for control. Gene expression data indicates successful knock-down of 
respective genes (Srf, Acta and Dmd ) and down-regulation of pertinent core clock genes 
(Per1 and Per2) and other down-stream targets for RhoA-actin-SRF (Nr1d1 and Acta1; 
housekeeping gene- Gapdh). Data normalised to NT siRNA; n=3; Two-way ANOVA with 






Figure 6. Schematic illustrating RhoA-actin-SRF signalling pathway.  
In healthy muscle, systemic cues activate RhoA in peripheral tissues which in turn regulates 
diurnal polymerisation (F-actin) and de-polymerisation (globular (G)-actin) of actin. During 
the de-polymerisation stage, G-actin preferentially binds to myocardin-related transcription 
factor (MRTF). However, when this shifts to the polymerisation phase, the G-actin pool 
diminishes and unbound MRTF translocates into the nucleus and influences expression of 
serum response factor (SRF). SRF activation regulates transcription of SRF target genes 
including the core clock genes- Per1 and Per2, as well as secondary loop clock genes- Rora1 
and Nr1d1, and cytoskeletal genes such as Acta. When dystrophin is absent, F-actin is not 
stable and the cell shifts to the de-polymerised state. G-actin binds to MRTF and therefore 






Supplementary Information  
Table S1. SiRNA and PCR Primer IDs or Sequences 
 
Figure S1. F/G actin ratios in C57BL10, and mdx and dKO littermates 
F/G-actin protein ratios from the tibialis anterior (TA) of 5 week old dKO were significantly 
lower than littermate mdx and C57BL10 animals (ZT1). N=3-4 for each for each genotype; 
One-way ANOVA with Bonferroni post-hoc test performed. Mean values reported with SEM; 





Figure S2. Utrophin protein and transcript levels altered in dystrophic models.  
Transcript levels (left), western blot quantification (middle) and representative western 
blots (right; total protein quantified for normalisation) for utrophin shown for (A) mdx and 
C57BL10 mice and (B) H2K 2B4 myotubes. (C) UTRN gene expression down-regulated in all 
but one DMD muscle biopsy sample. (D) Linear regression plotting PER1, PER2, and NR1D1 
versus UTRN gene expression indicates significant correlation pattern with PER1 (R= 0.1687) 
and PER2 (R= 0.4542). Data normalised to NT siRNA or C57BL10; Student’s t-test for 
comparisons between 2 groups (Two-tailed; ***p < 0.001, **p < 0.01, *p < 0.05). N=3-4. For 





Figure S3. In vitro dose response curves for Srf and Acta  
H2K 2B4 myotubes were transfected with 3nM, 30nM and 100nM of siRNA targeting the Srf, 
Acta and Dmd genes (Srf siRNA, blue and Acta siRNA grey), and a non-targeting (NT siRNA, 
black) siRNA was used for control. Gene expression data indicates significant and sustained 
knock-down of respective genes at low doses (housekeeping gene- Gapdh). Data normalised 
to NT siRNA; n=3; Two-way ANOVA with Bonferroni post-hoc test performed. Mean values 
reported with SEM; ***p < 0.001, **p < 0.01, *p < 0.05. 
 
 
 






